RASAL3 and prostate carcinoma: The Ras inhibitor RASAL3 showed epigenetic silencing in human prostate CAFs, which can lead to oncogenic Ras activity to drive glutamine synthesis mediated by macropinocytosis for uptake by prostate cancer cells, increased flux through the TCA cycle, and increased ATP generation and prostate cancer cell growth [47].